Bellicum Pharmaceuticals, Inc. (BLCM) EPS Estimated At $-0.59; Wespac Advisors Has Raised Altria Group (MO) Position By $419,880

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Logo

Analysts expect Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) to report $-0.59 EPS on March, 12.They anticipate $0.02 EPS change or 3.28% from last quarter’s $-0.61 EPS. After having $-0.55 EPS previously, Bellicum Pharmaceuticals, Inc.’s analysts see 7.27% EPS growth. The stock decreased 0.91% or $0.03 during the last trading session, reaching $3.26. About 135,240 shares traded. Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) has declined 56.89% since February 13, 2018 and is downtrending. It has underperformed by 56.89% the S&P500. Some Historical BLCM News: 13/03/2018 – BELLICUM PHARMACEUTICALS INC – QTRLY SHR LOSS $0.66; 08/05/2018 – Bellicum Pharmaceuticals 1Q Loss/Shr 68c; 20/03/2018 – Lifshitz & Miller LLP Announces Investigation of Atlas Financial Holdings, Inc., Bellicum Pharmaceuticals, Inc., Celgene Corpor; 11/04/2018 – Bellicum Announces Clinical Hold Lifted on U.S. Studies of BPX-501; 29/05/2018 – Bellicum Pharmaceuticals Appoints Shane Ward as General Counsel; 14/03/2018 – Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Bellicum Pharmaceuticals, Inc; 11/04/2018 – BELLICUM PHARMACEUTICALS INC – FDA CLINICAL HOLD DID NOT AFFECT BP-004 REGISTRATIONAL TRIAL IN EUROPE, WHICH IS FULLY ENROLLED; 13/03/2018 – BELLICUM PHARMA – BP-004 TRIAL DATA SUGGEST BPX-501 T CELLS MAY CONTRIBUTE TO DURABLE ANTI-LEUKEMIC EFFECT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA; 13/03/2018 – BELLICUM REPORTS BPX-501 INTERIM RESULTS IN PEDIATRIC PATIENTS; 11/04/2018 – BELLICUM PHARMACEUTICALS INC – BELLICUM WILL BE WORKING WITH U.S. CLINICAL SITES TO RESUME PATIENT RECRUITMENT BASED ON AMENDED PROTOCOLS

Wespac Advisors Llc increased Altria Group Inc (MO) stake by 109.46% reported in 2018Q3 SEC filing. Wespac Advisors Llc acquired 6,998 shares as Altria Group Inc (MO)’s stock declined 11.92%. The Wespac Advisors Llc holds 13,391 shares with $808,000 value, up from 6,393 last quarter. Altria Group Inc now has $91.83B valuation. The stock decreased 1.33% or $0.66 during the last trading session, reaching $49. About 9.10 million shares traded. Altria Group, Inc. (NYSE:MO) has declined 25.37% since February 13, 2018 and is downtrending. It has underperformed by 25.37% the S&P500. Some Historical MO News: 26/04/2018 – Altria Earnings Beat Even As Cigarette Sales Decline Further — MarketWatch; 17/05/2018 – ALTRIA GROUP INC – ANNOUNCES EXPANSION OF ITS $1 BLN SHARE REPURCHASE PROGRAM TO $2 BLN,; 17/05/2018 – ALTRIA GROUP INC – DECLARES REGULAR QUARTERLY DIVIDEND OF $0.70 PER SHARE; 13/03/2018 Baseball News Source: Altria Group Inc $MO Announces Dividend Increase – $0.70 Per Share; 17/05/2018 – ALTRIA CEO: FDA PMTA APPLICATION COULD COME AT ANY TIME; 17/05/2018 – ALTRIA ANNUAL MEETING OF SHAREHOLDERS ENDS; 22/05/2018 – Altria creates new `core’, `innovative’ tobacco units; 22/05/2018 – ALTRIA GROUP INC – NEW STRUCTURE INCLUDES CREATION OF A CHIEF GROWTH OFFICER FUNCTION; 26/04/2018 – Altria 1Q Net $1.89B; 26/04/2018 – Altria 1Q Marlboro Retail Share 43.2%

More notable recent Altria Group, Inc. (NYSE:MO) news were published by: which released: “Altria Continues To Fire Up Value And Profitability – Seeking Alpha” on February 13, 2019, also with their article: “Altria Q4 2018 Earnings Preview – Seeking Alpha” published on January 30, 2019, published: “MO is Breaking Below $47.50 Support After Bad News From the FDA –” on January 22, 2019. More interesting news about Altria Group, Inc. (NYSE:MO) were released by: and their article: “Altria Stock Analysis And Tobacco Sector Discussion (Video) – Seeking Alpha” published on January 16, 2019 as well as‘s news article titled: “Why the FDA Is Angry at Altria’s $13 Billion Juul Investment – Motley Fool” with publication date: January 15, 2019.

Investors sentiment increased to 0.93 in Q3 2018. Its up 0.11, from 0.82 in 2018Q2. It is positive, as 52 investors sold MO shares while 495 reduced holdings. 128 funds opened positions while 382 raised stakes. 1.17 billion shares or 1.41% more from 1.16 billion shares in 2018Q2 were reported. Whittier Tru Company Of Nevada Inc accumulated 78,389 shares. Deroy And Devereaux Private Counsel invested in 4,546 shares or 0.03% of the stock. Toronto Dominion Natl Bank reported 1.27M shares or 0.14% of all its holdings. Wagner Bowman invested in 34,104 shares. Salient Lta has 160,536 shares for 1.08% of their portfolio. Livingston Grp Asset Mgmt (Operating As Southport Management) has invested 0.13% in Altria Group, Inc. (NYSE:MO). The Texas-based Bancshares has invested 0.06% in Altria Group, Inc. (NYSE:MO). Welch Gru Ltd Llc invested 0.04% of its portfolio in Altria Group, Inc. (NYSE:MO). Oregon Public Employees Retirement Fund accumulated 511,488 shares. Massachusetts-based Nichols Pratt Advisers Llp Ma has invested 0.03% in Altria Group, Inc. (NYSE:MO). Panagora Asset Inc has invested 0.01% in Altria Group, Inc. (NYSE:MO). Pittenger Anderson invested 0.18% of its portfolio in Altria Group, Inc. (NYSE:MO). West Chester Capital Incorporated reported 24,365 shares. Vigilant Cap Mngmt Ltd Com owns 293 shares. Cadence Capital Mgmt Ltd Liability Com invested in 219,569 shares or 0.72% of the stock.

Since August 29, 2018, it had 0 buys, and 1 sale for $184,966 activity. DEVITRE DINYAR S had sold 3,165 shares worth $184,966.

Among 7 analysts covering Altria Group (NYSE:MO), 2 have Buy rating, 2 Sell and 3 Hold. Therefore 29% are positive. Altria Group had 8 analyst reports since August 24, 2018 according to SRatingsIntel. The firm has “Sell” rating given on Friday, December 21 by Citigroup. Jefferies downgraded the stock to “Hold” rating in Friday, August 24 report. The rating was downgraded by Cowen & Co on Monday, January 7 to “Market Perform”. Morgan Stanley downgraded it to “Underweight” rating and $45 target in Tuesday, January 22 report. The rating was maintained by Citigroup with “Neutral” on Friday, September 21. The firm has “Buy” rating given on Monday, October 29 by Argus Research.

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company has market cap of $141.36 million. It has three product candidates in clinical development: BPX-501, an adjunct T-cell therapy product candidate being evaluated in Phase I/II clinical trials in children and adults following a T-depleted, haploidentical hematopoietic stem cell transplant ; BPX-601, a GoCAR-T product candidate in Phase I development for solid tumors expressing the prostate stem cell antigen; and BPX-701, a T cell receptors (TCR) product candidate in Phase I development for AML with future development potential for treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. It currently has negative earnings. The firm has collaboration agreements with Adaptimmune Therapeutics plc to evaluate, develop, and commercialize T-cell therapies; Ospedale Pediatrico Bambino Gesú for the design and development of various T cell immunotherapies; and Academisch Ziekenhuis Leiden for research to discover and validate high-affinity TCR product candidates targeting various cancer-associated antigens.

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Ratings Chart